D
Daniel H. Sterman
Researcher at New York University
Publications - 176
Citations - 8762
Daniel H. Sterman is an academic researcher from New York University. The author has contributed to research in topics: Mesothelioma & Lung cancer. The author has an hindex of 47, co-authored 168 publications receiving 7535 citations. Previous affiliations of Daniel H. Sterman include Children's Hospital of Philadelphia & Université de Montréal.
Papers
More filters
Journal ArticleDOI
Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers
Andrew L. Pecora,Naiyer A. Rizvi,Gary I. Cohen,Neal J. Meropol,Daniel H. Sterman,John L. Marshall,Stuart L. Goldberg,Peter A. Gross,James D. O'Neil,William S. Groene,M. Scot Roberts,Harvey Rabin,Michael K. Bamat,Robert M. Lorence +13 more
TL;DR: The maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer warrants further study as a novel therapeutic agent for cancer patients.
Journal ArticleDOI
Tumors of the mediastinum.
TL;DR: The anatomy of the mediastinum is reviewed as well as the different clinical, radiographic, and prognostic features, and therapeutic options of the most commonly encountered masses.
Journal ArticleDOI
Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype.
Leopoldo N. Segal,Jose C. Clemente,Jun Chieh J. Tsay,Sergei B. Koralov,Brian C. Keller,Benjamin G. Wu,Yonghua Li,Nan Shen,Elodie Ghedin,Alison Morris,P. Diaz,Laurence Huang,William R. Wikoff,Carles Ubeda,Alejandro Artacho,William N. Rom,Daniel H. Sterman,Ronald G. Collman,Martin J. Blaser,Michael D. Weiden +19 more
TL;DR: P pneumotypeSPT was associated with a distinct metabolic profile, enhanced expression of inflammatory cytokines, a pro-inflammatory phenotype characterized by elevated Th-17 lymphocytes and, conversely, a blunted alveolar macrophage TLR4 response.
Journal ArticleDOI
Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma
Daniel H. Sterman,Joseph Treat,Leslie A. Litzky,Kunjlata M. Amin,Laura Coonrod,Katherine L. Molnar-Kimber,Adri Recio,Linda Knox,James M. Wilson,Steven M. Albelda,Larry R. Kaiser +10 more
TL;DR: It is demonstrated that intrapleural administration of an adenoviral vector containing the HSVtk gene is well tolerated and results in detectable gene transfer when delivered at high doses.
Journal ArticleDOI
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Dung T. Le,Dirk G. Brockstedt,Ran Nir-Paz,Johannes Hampl,Shruti Mathur,John Nemunaitis,Daniel H. Sterman,Raffit Hassan,Eric R. Lutz,Bentley Moyer,Martin Giedlin,Jana Lynn Louis,Elizabeth A. Sugar,Alice Pons,Andrea L. Cox,Jordana Levine,Aimee Murphy,Peter B. Illei,Thomas W. Dubensky,Joseph E. Eiden,Elizabeth M. Jaffee,Daniel A. Laheru +21 more
TL;DR: Two phase I studies test ANZ-100 and CRS-207 in subjects with liver metastases and mesothelin-expressing cancers, respectively, finding that administration was safe and resulted in immune activation.